Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.

Philippe Merle,Julien Edeline,Mohamed Bouattour,Ann-Lii Cheng,Stephen L. Chan,Thomas Yau,Marcelo Garrido,Jennifer J. Knox,Bruno Daniele,Andrew X. Zhu,Valeriy Breder,Ho Yeong Lim,Sadahisa Ogasawara,Abby B. Siegel,Ahmadur Rahman,Ziwen Wei,Richard S. Finn

Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.

2021

Philippe Merle
Julien Edeline
Mohamed Bouattour
Ann-Lii Cheng
Stephen L. Chan
Thomas Yau
Marcelo Garrido
Jennifer J. Knox
Bruno Daniele
Andrew X. Zhu
Valeriy Breder
Ho Yeong Lim
Sadahisa Ogasawara
Abby B. Siegel
Ahmadur Rahman
Ziwen Wei
Richard S. Finn

268Background: KEYNOTE-240 (NCT02702401) examined the anti-PD-1 antibody pembro and demonstrated improvement in OS and PFS vs pbo in pts with aHCC previously treated with sorafenib. However, the st...

Keywords:

Medicine
Internal medicine
Placebo
Sorafenib
Gastroenterology
Pembrolizumab
previously treated
in patient
Hepatocellular carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations